Journal
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Volume 15, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/17562848221138676
Keywords
gastrointestinal microbiome; metabolites; non-alcoholic fatty liver disease; treatment options
Categories
Funding
- National Natural Science Foundation of China [82070609]
Ask authors/readers for more resources
This review explores the interaction between microbial products and non-alcoholic fatty liver disease (NAFLD), as well as the regulatory role of existing NAFLD therapies on metabolite levels. It is found that microbial metabolites can regulate host lipid, glucose, and bile acid metabolic homeostasis through various pathways, and have the potential to alleviate NAFLD. Therefore, targeting these metabolites may be beneficial in relieving NAFLD.
Over the past two decades, non-alcoholic fatty liver disease (NAFLD) has become a leading burden of hepatocellular carcinoma and liver transplantation. Although the exact pathogenesis of NAFLD has not been fully elucidated, recent hypotheses placed more emphasis on the crucial role of the gut microbiome and its derivatives. Reportedly, microbial metabolites such as short-chain fatty acids, amino acid metabolites (indole and its derivatives), bile acids (BAs), trimethylamine N-oxide (TMAO), and endogenous ethanol exhibit sophisticated bioactive properties. These molecules regulate host lipid, glucose, and BAs metabolic homeostasis via modulating nutrient absorption, energy expenditure, inflammation, and the neuroendocrine axis. Consequently, a broad range of research has studied the therapeutic effects of microbiota-derived metabolites. In this review, we explore the interaction of microbial products and NAFLD. We also discuss the regulatory role of existing NAFLD therapies on metabolite levels and investigate the potential of targeting those metabolites to relieve NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available